FOLH1 and prostate cancer: This showed that rA1M does not interfere with the uptake nor therapeutic effect of [177Lu]Lu-PSMA-617 in our preclinical model of prostate cancer as no significant differences could be seen between mice given vehicle or rA1M together with [177Lu]Lu-PSMA-617.